Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial

202342 citationsJournal Articlegold Open Access

Authors

Yangqing Zhan · Guangzhou Experimental Station

Zhengshi Lin · Guangzhou Experimental Station

Jingyi Liang · Guangzhou Experimental Station

Ruilin Sun · Guangdong Provincial Hospital of Traditional Chinese Medicine

Yueping Li · Guangzhou Eighth People's Hospital

Bingliang Lin · Sun Yat-sen University

Fangqi Ge

Abstract

This study was funded by the National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine, Guangdong Science and Technology Foundation, Guangzhou Science and Technology Planning Project and R&D Program of Guangzhou Laboratory.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies SARS-CoV-2 detection and testing

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: EClinicalMedicine

Volume 67, pp. 102359-102359

DOI: 10.1016/j.eclinm.2023.102359

Field-Weighted Citation Impact: 8.15